Trial Profile
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASCENT
- Sponsors Gilead Sciences; Immunomedics
- 09 Dec 2023 Results of pooled analysis from TROPiCS-02, IMMU-132-01, and ASCENT presented at the 46th Annual San Antonio Breast Cancer Symposium.
- 09 Nov 2022 Results(n=479) assessing Health Utilities Associated With Sacituzumab Govitecan (SG) for Treating Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 18 Oct 2022 Results (n=419) of an analysis assessing health-related quality of life published in the European Journal of Cancer